Daglutril

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328021

CAS#: 182821-27-8

Description: Daglutril, also known as SLV-306, is NEP/ECE inhibitor potentially for the treatment of hypertension, heart failure andpulmonary. SLV-306 (daglutril) inhibits systemic conversion of big endothelin-1 in humans.


Chemical Structure

img
Daglutril
CAS# 182821-27-8

Theoretical Analysis

MedKoo Cat#: 328021
Name: Daglutril
CAS#: 182821-27-8
Chemical Formula: C31H38N2O6
Exact Mass: 534.273
Molecular Weight: 534.653
Elemental Analysis: C, 69.64; H, 7.16; N, 5.24; O, 17.95

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Daglutril; SLV-306; SLV 306; SLV306.

IUPAC/Chemical Name: ((3S)-3-{1-((2R)-2-Ethoxycarbonyl-4-phenylbutyl)cyclopentanecarboxamido}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)acetic acid

InChi Key: XMQODGUTLZXUGZ-RPBOFIJWSA-N

InChi Code: InChI=1S/C31H38N2O6/c1-2-39-29(37)24(15-14-22-10-4-3-5-11-22)20-31(18-8-9-19-31)30(38)32-25-17-16-23-12-6-7-13-26(23)33(28(25)36)21-27(34)35/h3-7,10-13,24-25H,2,8-9,14-21H2,1H3,(H,32,38)(H,34,35)/t24-,25+/m1/s1

SMILES Code: O=C(O)CN1C([C@@H](NC(C2(C[C@H](C(OCC)=O)CCC3=CC=CC=C3)CCCC2)=O)CCC4=CC=CC=C41)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 534.653 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Márquez DF, Ruiz-Hurtado G, Ruilope LM, Segura J. An update of the blockade of the renin angiotensin aldosterone system in clinical practice. Expert Opin Pharmacother. 2015;16(15):2283-92. doi: 10.1517/14656566.2015.1079623. Epub 2015 Sep 7. Review. PubMed PMID: 26389772.

2: Maguire JJ, Davenport AP. Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. Br J Pharmacol. 2014 Dec;171(24):5555-72. doi: 10.1111/bph.12874. Epub 2014 Nov 24. Review. PubMed PMID: 25131455; PubMed Central PMCID: PMC4290702.

3: Parvanova A, van der Meer IM, Iliev I, Perna A, Gaspari F, Trevisan R, Bossi A, Remuzzi G, Benigni A, Ruggenenti P; Daglutril in Diabetic Nephropathy Study Group. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013 Sep;1(1):19-27. doi: 10.1016/S2213-8587(13)70029-9. Epub 2013 Jun 13. PubMed PMID: 24622263.

4: Laurent S. Daglutril for treatment of renal damage in hypertensive patients with type 2 diabetes: disappointment or hope? Lancet Diabetes Endocrinol. 2013 Sep;1(1):2-3. doi: 10.1016/S2213-8587(13)70036-6. Epub 2013 Jun 13. PubMed PMID: 24622251.

5: Monge M, Lorthioir A, Bobrie G, Azizi M. New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension. J Renin Angiotensin Aldosterone Syst. 2013 Dec;14(4):285-9. doi: 10.1177/1470320313513408. Epub 2013 Nov 12. Review. PubMed PMID: 24222656.

6: Seed A, Kuc RE, Maguire JJ, Hillier C, Johnston F, Essers H, de Voogd HJ, McMurray J, Davenport AP. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8. doi: 10.1016/j.lfs.2012.03.022. Epub 2012 Mar 28. PubMed PMID: 22480515.

7: Thöne-Reinke C, Simon K, Richter CM, Godes M, Neumayer HH, Thormählen D, Hocher B. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S76-9. PubMed PMID: 15838365.

8: Emoto N. [Physiological and pathophysiological roles of the endothelin converting enzymes]. Nihon Rinsho. 2004 Sep;62 Suppl 9:636-9. Review. Japanese. PubMed PMID: 15506464.

9: Dickstein K, De Voogd HJ, Miric MP, Willenbrock R, Mitrovic V, Pacher R, Koopman PA. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol. 2004 Jul 15;94(2):237-9. PubMed PMID: 15246912.

10: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 May;25(4):317-40. PubMed PMID: 12808477.

11: Tabrizchi R. SLV-306. Solvay. Curr Opin Investig Drugs. 2003 Mar;4(3):329-32. Review. PubMed PMID: 12735234.

12: Gray GA, Battistini B, Webb DJ. Endothelins are potent vasoconstrictors, and much more besides. Trends Pharmacol Sci. 2000 Feb;21(2):38-40. PubMed PMID: 10733432.